PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Follow PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Share on
Copy link to clipboard

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selec…

PVI, PeerView Institute for Medical Education


    • Sep 22, 2022 LATEST EPISODE
    • weekdays NEW EPISODES
    • 48m AVG DURATION
    • 272 EPISODES


    More podcasts from PVI, PeerView Institute for Medical Education

    Search for episodes from PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast with a specific topic:

    Latest episodes from PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

    Jeffrey L. Neul, MD, PhD - Encouraging News in Rett Syndrome: Steps Towards a Timely, Accurate Diagnosis and Treatment Breakthroughs

    Play Episode Listen Later Sep 22, 2022 27:47


    Go online to PeerView.com/QSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Rett syndrome discusses the diagnosis and management of this rare disease, as well as the latest data on emerging treatment options. A 3D animation offers an overview of MECP2 mutation, hypothesized to be a major contributor to the CNS manifestations of Rett syndrome. Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to provide a timely diagnosis of Rett syndrome in infants demonstrating subtle signs and symptoms; Implement consensus recommendations on the age-specific management of patients with Rett syndrome; and Evaluate the evidence surrounding the safety, efficacy, and tolerability of emerging pharmacologic treatment options to consider implementing these novel therapies when they become available.

    David Staskin, MD - Controlling the Urgency Emergency, Restoring QOL: Safe and Effective Management of Overactive Bladder

    Play Episode Listen Later Sep 19, 2022 29:44


    Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

    Alexander Drilon, MD - Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

    Play Episode Listen Later Sep 19, 2022 60:18


    Go online to PeerView.com/CNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC. Upon completion of this activity, participants should be better able to: Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions; Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy; Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC; and Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences.

    Sarah S. Chisolm, MD - Taking a New Look at Prurigo Nodularis: How Is Emerging Evidence Regarding Disease Pathophysiology and Treatment Influencing Patient Care?

    Play Episode Listen Later Sep 6, 2022 63:04


    Go online to PeerView.com/ZXX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) causes intensely itchy, painful bumps leading to scratching, bleeding, and thickening of the nodules, with negative effects on sleep, mental health, activities of daily living, social interaction, and quality of life. There are no approved treatments for PN, but several agents in late-stage clinical trials offer hope to patients with this burdensome disease. At a recent live PeerView MasterClass & Practicum, a panel of PN experts offered evidence-based, practical guidance on current diagnostic and treatment strategies and the latest clinical data regarding novel therapies. The discussion was enhanced by a 3D animation depicting PN pathophysiology and patient videos providing perspectives on the burdens of disease and treatment experience. Upon completion of this activity, participants should be better able to: Recognize how the signs and symptoms of prurigo nodularis (PN) impact patient quality of life; Explain how type 2 inflammation may play a role in the pathophysiology of PN; Describe current and emerging treatment options for PN in the context of mechanism of action, efficacy, and safety; and Develop individualized treatment plans for PN using currently available therapies and appropriately incorporating novel agents as they become available.

    R. Sharon Chinthrajah, MD - IgE-Mediated Food Allergies: Improving Patient Quality of Life Through a Multidisciplinary Approach as a New Era of Treatment Dawns

    Play Episode Listen Later Sep 6, 2022 32:47


    Go online to PeerView.com/QER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current standards of care for managing food allergies require strict avoidance measures and prompt treatment of allergic reactions with emergency medications. However, oral immunotherapies and biologic agents are currently in development for the treatment of IgE-mediated food allergies, replacing the need for oral food challenges. Our expert faculty will share strategies for optimal clinical decision-making for patients with food allergy that is based on the latest evidence, best practice recommendations, and effective multidisciplinary collaboration. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of IgE-mediated food allergy and how these insights into underlying mechanisms can translate to the use of biomarkers to allow more personalized treatment for patients; Apply strategies to differentially diagnose patients with IgE-mediated food allergies using the latest criteria and expert recommendations; Identify patients with IgE-mediated food allergies who might be eligible for novel and emerging treatments and/or enrollment in clinical trials based on the latest evidence on efficacy and safety; and Employ a multidisciplinary approach to the treatment of patients with food allergy to optimize care and improve quality of life.

    Wanda Phipatanakul, MD, MS - Controlling Moderate to Severe Asthma Across the Lifespan in an Ever-Evolving Treatment Landscape: How Much Do You Know?

    Play Episode Listen Later Sep 2, 2022 31:45


    Go online to PeerView.com/QYV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Asthma is a common, chronic, and heterogeneous disease that can result in poor quality of life and severe, life-threatening exacerbations despite standard controller therapy. Type 2 inflammation, mediated by cytokines such as IL-4, IL-5, and IL-13, occurs in about 50% of patients with asthma and has emerged as a unifying feature of classically defined allergic diseases and a range of other inflammatory diseases. In this activity, an expert explains the advances in understanding of the pathogenesis of asthma and the targeted treatments that have been developed as a result. You will hear expert insights into the use of available and emerging biologic therapies, including how to identify children and adults who may be eligible for these therapies. Upon completion of this activity, participants should be better able to: Identify patients who would likely benefit from targeted therapy, considering the relationship between type 2 inflammation, moderate to severe asthma, and comorbid conditions such as atopic dermatitis; Incorporate evidence-based and guideline-directed treatment for pediatric and adult patients with moderate to severe asthma into customized management plans; and Use techniques to educate and communicate with patients and caregivers to engage them in care and improve adherence to individualized treatment plans.

    Cedric "Jamie" Rutland, MD - Addressing the Underlying Inflammation of Non–Cystic Fibrosis Bronchiectasis: Exploring Novel Treatments to Change Disease Course for Patients and Improve Quality of Life

    Play Episode Listen Later Sep 2, 2022 28:26


    Go online to PeerView.com/HTX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non-cystic fibrosis bronchiectasis is a long-term respiratory condition with a significant impact on quality of life, morbidity, mortality, and use of healthcare resources. The disease manifests as chronic airway inflammation, impaired mucociliary clearance, and structural lung damage leading to recurrent infections, persistent cough, sputum production, and exacerbations. The prevalence of bronchiectasis has been on the rise. Evolving insights into the pathophysiology of bronchiectasis have led to the development of novel and emerging agents to address the underlying inflammation, with the potential of changing the treatment landscape. In this animated activity, you will learn how to optimize clinical decision-making for patients with non-cystic fibrosis bronchiectasis that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Apply current guideline recommendations to the diagnosis and treatment of patients with bronchiectasis, with a goal of identifying and treating underlying causes; Describe the underlying mechanisms believed to contribute to inflammation in non–cystic fibrosis bronchiectasis and their correlation to emerging treatments; Assess recent clinical trial data concerning efficacy and safety of novel and emerging treatment options for non–cystic fibrosis bronchiectasis; and Develop strategies for preventing and treating exacerbations (eg, airway clearance, use of antibiotics, corticosteroids) in patients with non–cystic fibrosis bronchiectasis based on the latest expert recommendations using a personalized approach.

    Robert Sidbury, MD, MPH - Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

    Play Episode Listen Later Sep 1, 2022 42:08


    Go online to PeerView.com/WVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD); Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD; Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD; Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD; and Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects.

    Rupa R. Patel, MD, MPH, DTM&H - A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

    Play Episode Listen Later Aug 29, 2022 37:14


    Go online to PeerView.com/AHC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures. Upon completion of this activity, participants should be better able to: Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19; Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures; and Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team.

    Julie V. Philley, MD; Kevin Winthrop, MD, MPH - Confronting the Challenges of Nontuberculous Mycobacterial Lung Disease: Expert Strategies for Reducing Diagnostic Delays and Improving Adherence to Guideline-Based Treatment

    Play Episode Listen Later Aug 29, 2022 34:58


    Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

    Aditya Bardia, MD, MPH - Candid Conversations and Clinical Consults in Community Context: Practical Guidance for Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer Clinical Care

    Play Episode Listen Later Aug 29, 2022 50:09


    Go online to PeerView.com/JWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the management of patients with hormone receptor–positive breast cancer discuss the latest advances with TROP2-targeting antibody–drug conjugates (ADCs). Produced in collaboration with Living Beyond Breast Cancer and METAvivor, this program features a patient explaining her journey from diagnosis to participation in an important clinical trial, and faculty providing practical guidance for using TROP2-targeting ADCs in the individualized care of patients with breast cancer. Upon completion of this activity, participants should be better able to: Summarize the rationale, mechanism of action, and expanding clinical role of TROP2-targeting therapies in breast cancer; Integrate the latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Develop individualized management plans for patients with breast cancer that incorporate TROP2-targeting therapies using the latest clinical evidence and current practice guidelines to inform daily practice; and Apply a team-based approach to care that incorporates shared decision-making and patient counseling/education and leverages effective interprofessional collaboration and care coordination.

    Professor Perry Elliott, MBBS, MD, FRCP, FESC, FACC - New Therapies, New Hope: Evolving Strategies for Improving Outcomes and Quality of Life in Patients With Hypertrophic Cardiomyopathy

    Play Episode Listen Later Aug 25, 2022 49:20


    Go online to PeerView.com/WKU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 15 to 20 million people worldwide. However, it remains frequently undetected, because its symptoms are often nonspecific or mistaken for more common conditions. In this discussion-based activity, leading experts on HCM get to the heart of the matter, diagnosis and treatment, as they review guideline recommendations on imaging for diagnosis and examine current and novel treatment options, including small-molecule myosin inhibitors, as a means to improve patient outcomes and quality of life. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance using appropriate cardiac imaging techniques; Apply the latest recommendations and current guidance for diagnosing, evaluating, and managing patients with HCM in a collaborative care model; and Incorporate emerging therapies for managing patients with HCM based on their efficacy, safety, and ability to address the unmet needs of patients and the pathophysiology of HCM.

    Domenica M. Rubino, MD - Getting Ahead of the Curve: Identifying and Managing Obesity in Primary Care

    Play Episode Listen Later Aug 11, 2022 60:56


    Go online to PeerView.com/DBP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on obesity management discusses current evidence for anti-obesity medications and shares evidence-based strategies to individualize weight-loss regimens and improve health outcomes. Upon completion of this activity, participants should be better able to: Recognize the role of weight-loss pharmacotherapy for reducing risks and addressing obesity as a chronic disease, including effects on appetite regulation, metabolic adaptation, and preventing/managing obesity-related complications, adjunct to lifestyle modification; Assess current guidance and available long-term efficacy and safety data for current and emerging weight-loss pharmacotherapies in people with or at risk for obesity; and Incorporate weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.

    Richard Beaser, MD - A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes

    Play Episode Listen Later Aug 10, 2022 85:41


    Go online to PeerView.com/TFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Who holds the key that can unlock the door to vision-saving treatments for patients with diabetic retinopathy (DR) and diabetic macular edema (DME)? The answer is primary diabetes care professionals: Timely screening and referral to eye care professionals can make a real difference between good vision and blindness for patients with DR/DME. The diagnosis and treatment of DR/DME has advanced greatly in the last decade. What can endocrinologists, diabetologists, and primary diabetes care professionals tell their patients to expect when they meet with a retina specialist? In this activity, based on a recent PeerView Live event, leading experts take a well-rounded look at the screening, diagnosis, and referral for treatment of individuals with DR/DME, including a practical review of the evidence for current and emerging treatment options. The experts discuss patient cases with varying degrees of urgency for referral, offering a glimpse into how decisions made by primary diabetes care professionals can speed access to the appropriate eye care professional to directly benefit and improve outcomes for patients with, or at risk for, DR/DME. Upon completion of this activity, participants should be better able to: Describe the roles of diabetes specialists in the screening and referral process for DR/DME and other diabetic eye diseases; Coordinate timely and appropriate referrals to eye care specialists who can utilize effective treatment regimens for DR/DME and other diabetic eye diseases; and Incorporate interprofessional and multidisciplinary strategies to overcome barriers to referral using an integrated system of care approach for screening, diagnosis, and treatment of vision-threatening diabetic eye complications such as DR/DME.

    Bruce Cree, MD, PhD, MAS - Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

    Play Episode Listen Later Aug 5, 2022 60:54


    Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient's disease activity, treatment preferences and goals, and therapeutic options.

    Leonard H. Calabrese, DO - Recognition and Management of Axial Spondyloarthritis: Best Practices for Family Medicine Physicians

    Play Episode Listen Later Aug 5, 2022 43:14


    Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

    Joan T. Merrill, MD - New Directions in Kinase Inhibition in Systemic Lupus Erythematosus: Emerging Evidence From Copenhagen

    Play Episode Listen Later Aug 2, 2022 29:51


    Go online to PeerView.com/XJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic lupus erythematosus (SLE) is an autoimmune disease associated with substantial morbidity and mortality, especially in women. The disease causes progressive damage to multiple organ systems and reduces quality of life. Improving your understanding of SLE heterogeneity at the clinical and mechanistic level can drive significant improvements across the care spectrum. In this expert-driven activity, you will hear the latest clinical evidence presented during the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress in Copenhagen, Denmark, with regard to the current treatment options for SLE and the potential for TYK2 inhibitors to change SLE management. Upon completion of this activity, participants should be better able to: Recognize the burden of SLE and the impact of delayed or suboptimal treatment on patient outcomes; Describe the mechanistic rationale and recent safety and efficacy data supporting a role for targeting TYK2 and BTK as potential therapeutic approaches in SLE; and Identify SLE patients who might benefit from emerging TYK2 and BTK inhibition strategies through clinical trial enrollment and recognizing potential implications for a future treatment paradigm.

    Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know

    Play Episode Listen Later Aug 2, 2022 63:22


    Go online to PeerView.com/REA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Listen to our expert faculty as they discuss new and emerging therapies for AA and AD, with a focus on mechanisms of action, efficacy and safety profiles, nuances of administration and use, and risk:benefit profile. You will also hear about novel therapies in late-stage development for the treatment of moderate to severe AD and AA. The Late Night inExchange format is designed to meet the educational needs of clinicians with practice-relevant education presented in an engaging multi-faculty discussion format that brings knowledge to life. Through this format, learners will be better able to see how conceptual knowledge of AA and AD translates to actual practice. Upon completion of this activity, participants should be better able to: Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities; Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets; Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile; and Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.

    Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice

    Play Episode Listen Later Jul 22, 2022 25:38


    Go online to PeerView.com/DGJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL. Upon completion of this activity, participants should be better able to: Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs; Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations; and Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care.

    Shmuel Shoham, MD - Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge

    Play Episode Listen Later Jul 21, 2022 48:31


    Go online to PeerView.com/EWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Solid organ transplant recipients may be at increased risk for COVID-19 because they are immunosuppressed and less likely to mount effective immune responses to vaccination. In this educational symposium based on a live event, a panel of expert faculty address the identification of transplant patients who would likely derive benefit from anti-SARS-CoV-2 monoclonal antibodies (mAbs) and strategies that can be used to overcome barriers to COVID-19 pre-exposure prophylaxis access. In addition, they provide guidance on mAb qualities and clinical profiles and shared decision-making strategies to customize mAb pre-exposure prophylaxis at the point of care for transplant recipients needing protection against COVID-19. After participating in this activity, the learner will demonstrate the ability to: Identify post-transplant patients who would likely derive benefit from pre-exposure prophylaxis with anti-SARS-CoV-2 monoclonal antibodies (mAbs); Use strategies to overcome barriers to COVID-19 pre-exposure prophylaxis access for post-transplant patients; and Incorporate evidence-based recommendations and guidelines, mAb qualities and clinical profiles, and shared decision-making into strategies to customize mAb pre-exposure prophylaxis at point of care for post-transplant patients needing protection against COVID-19.

    Toni K. Choueiri, MD - Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care

    Play Episode Listen Later Jul 19, 2022 86:54


    Go online to PeerView.com/TJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid expansion of the renal cell carcinoma (RCC) therapeutic landscape has opened doors for clinical practice advancements for medical and urologic oncologists. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC as well. Designed to bridge the gap between theory and practice, this CME/MOC-certified educational activity, in partnership with KCCure, features expert guidance on how oncologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety of settings. Upon completion of this activity, participants should be better able to: Assess the therapeutic roles of and key efficacy and safety evidence on novel and emerging systemic therapy strategies for patients with localized or advanced/metastatic RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, guideline recommendations, and patient-, disease- and treatment-specific factors; Integrate evidence-based strategies and best practices to recognize, mitigate and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC.

    David Alain Wohl, MD - Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities

    Play Episode Listen Later Jul 19, 2022 34:39


    Go online to PeerView.com/BED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women. Upon completion of this activity, participants should be better able to: Incorporate clinical data on pre-exposure prophylaxis (PrEP) for HIV into culturally competent educational and counseling strategies to improve the uptake of PrEP in vulnerable populations, including Black women, Black/Latinx same-gender loving men, and transgender men and women; Facilitate access to PrEP among Black women, Black/Latinx same-gender loving men, and transgender men and women; and Use PrEP as part of a broader strategy to reduce disparities in HIV incidence in Black women, Black/Latinx same-gender loving men, and transgender men and women.

    David Weidman, MD - Therapeutic Advances in the Early Treatment of Alzheimer's Disease: Expert Insights on Novel Biomarkers and Emerging Disease-Modifying Therapies

    Play Episode Listen Later Jul 11, 2022 36:55


    Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

    Lisa H. Lancaster, MD - The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management

    Play Episode Listen Later Jul 11, 2022 34:01


    Go online to PeerView.com/TDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulmonary function tests, and high-resolution computed tomography. Until recently, therapy for SSc-ILD has been limited to supportive care and immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic pulmonary fibrosis (IPF) have either received approval, or are in development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and has many comorbidities, interprofessional management is essential from diagnosis throughout the disease course. In this expert-led activity, you will be able to self-assess your baseline levels of understanding, skill, and confidence, resulting in a tailored educational experience focused on the areas where you need it most. Upon completion of this activity, participants should be better able to: Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing, Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team, Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD.

    Reynold A. Panettieri, Jr., MD - The Future of Severe Asthma Treatment Is Here: Expert Insights on the Rationale for Targeting Epithelial Alarmins

    Play Episode Listen Later Jul 11, 2022 31:42


    Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathophysiology of severe asthma, particularly with regard to the role of epithelial alarmins in the development of severe asthma. Upon completion of this activity, participants should be better able to: Discuss the rationale for the use of therapeutic options that target epithelial alarmins, including TSLP, IL-33, and IL-25, for the treatment of severe asthma, Employ the latest pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe asthma, Develop treatment plans for patients with severe asthma, particularly those whose disease remains uncontrolled despite treatment, based on the latest clinical evidence with regard to novel and emerging therapies.

    Jeanne M. Palmer, MD - The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting

    Play Episode Listen Later Jul 8, 2022 63:11


    Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.

    Petros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease Continuum

    Play Episode Listen Later Jun 24, 2022 86:20


    Go online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the presence of immune-related adverse events (irAEs) in some patients linger after the end of therapy and limit the possible subsequent use of ADCs or FGFR inhibitors? To answer these questions, experts in bladder cancer highlight strategies for optimal care of patients in light of current evidence on and indications for use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Summarize the current roles, mechanisms of action, and key evidence pertaining to novel systemic therapies for patients with localized or metastatic bladder cancer, such as immunotherapies, small molecule targeted therapies, and antibody-drug conjugates, among others, Plan personalized treatment algorithms for patients with localized or metastatic urothelial cancer that incorporate novel and emerging therapies, updated guideline recommendations, and patient-, disease-, and treatment-specific factors, Implement evidence-based strategies and expert recommendations to prevent, mitigate and/or manage treatment-related adverse events that may occur among patients receiving novel systemic therapies for bladder cancer.

    Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

    Play Episode Listen Later Jun 14, 2022 81:08


    Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

    April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Fine-Tuning the JAK/STAT Pathway in Psoriasis: Safely Targeting the Underlying Mechanisms of Disease With TYK2 Inhibition

    Play Episode Listen Later Jun 14, 2022 62:10


    Go online to PeerView.com/CCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss the role of the JAK/STAT pathway in psoriasis, as well as treatment with novel kinase inhibitors for the management of patients with psoriasis. Upon completion of this activity, participants should be better able to: Describe and differentiate targeting of the TYK2, JAK1, JAK2, and JAK3 kinases and the correlation to emerging therapies for the treatment of moderate to severe psoriasis, Summarize recent efficacy and safety data for current and emerging therapies for the treatment of moderate to severe psoriasis, Recommend treatment for patients with moderate to severe psoriasis according to the latest guidelines and clinical evidence, particularly as emerging therapies become available.

    Liana G. Apostolova, MS, MD, FAAN - Accelerating Progress in the Treatment of Alzheimer's Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer's Disease?

    Play Episode Listen Later May 27, 2022 104:10


    Go online to PeerView.com/JYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating, progressive neurodegenerative disorder affecting 10% of people over age 65 and increasing in global prevalence. Recent advances in disease-modifying therapies have opened the door to the possibility of treatment approaches that can slow or prevent disease progression and improve patient outcomes. Now, with several anti–amyloid beta (Aβ) monoclonal antibodies in late-stage development, there is hope for families, clinicians, and researchers. The greatest likelihood of treatment success lies in timely diagnosis and early intervention. In this activity, based on a live symposium held at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases in Barcelona, Spain, an international panel of experts will discuss the importance of early recognition and diagnosis of AD and present the latest evidence on validated and emerging biomarkers that can aid in the early diagnosis of AD. They will also explore the mechanisms of action, efficacy, and safety data for promising disease-modifying therapies in development for the treatment of AD. Using patient case examples to frame the discussion, the expert faculty panel will provide practical guidance on how clinicians can effectively and safely integrate new diagnostic tools and disease-modifying therapies into clinical practice. Upon completion of this activity, participants should be better able to: Describe the rationale for identifying patients at risk for Alzheimer's disease (AD) early in the disease course, Utilize validated neuroimaging techniques and molecular biomarkers to make early and accurate neuropathological diagnoses of AD, Select appropriate AD patients who may benefit from novel disease-modifying therapies based on an understanding of their respective mechanisms of action, efficacy, and safety profiles.

    Brett King, MD, PhD - Addressing Healthcare Disparities and Optimizing Patient Outcomes in Atopic Dermatitis and Alopecia Areata: Expert Insight on How to Improve Access and Quality of Care

    Play Episode Listen Later May 26, 2022 85:03


    Go online to PeerView.com/TJZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss strategies to optimize patient outcomes in atopic dermatitis and alopecia areata. Upon completion of this activity, participants should be better able to: Appropriately diagnose atopic dermatitis (AD) and alopecia areata (AA) and assess severity to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities, Describe current and emerging treatments for AD and AA in the context of mechanism of action, efficacy and safety profile, dosage and administration, and other factors relevant to clinical use, Utilize available resources to identify and overcome racial and ethnic health disparities in the management of AD and AA and ultimately improve health outcomes in under-represented populations.

    Rajiv Agarwal, MD, MS - A Renewed Look at MRA Therapy: Improving Renal Outcomes and Reducing Risks in Patients With Type 2 Diabetes

    Play Episode Listen Later May 26, 2022 36:01


    Go online to PeerView.com/JNH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert nephrologist examines the pathophysiology of chronic kidney disease (CKD) and the effects of mineralocorticoid receptor overactivation in patients with type 2 diabetes (T2D) to offer practical strategies for identifying which patients with CKD and T2D may benefit from treatment with nonsteroidal MRAs. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of CKD progression and the effects of mineralocorticoid receptor overactivation in patients with T2D, Compare the mechanism of action, potency, selectivity, and physiological distribution of steroidal and nonsteroidal MRAs, Identify patients with CKD and T2D that may derive specific benefit from treatment with nonsteroidal MRAs.

    Sarina Elmariah, MD, PhD, MPH - Addressing the Burden of Prurigo Nodularis: Expert Insight on Disease Pathogenesis and the Clinical Potential of Novel Therapeutic Options

    Play Episode Listen Later May 25, 2022 43:01


    Go online to PeerView.com/DTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules symmetrically distributed on the trunk and extremities. PN is defined by intense pruritus lasting ≥6 weeks, history of repeated scratching, and subsequent development of pruritic, elevated, firm, and nodular skin lesions, in a vicious itch–scratch cycle. The intense itch associated with PN leads to sleep disturbances and reduced social participation and work productivity, resulting in a drastically reduced quality of life and psychosocial disturbances. Unfortunately, these issues experienced among patients with PN are further compounded by the lack of effective treatment options. In this activity, based on a recent live educational symposium, a panel of experts addresses real-world questions and dilemmas faced by providers and the PN patients for whom they care. By providing practical guidance on how to effectively integrate the latest evidence and expert recommendations into real-world clinical scenarios, this activity provides participating clinicians with the necessary tools to effectively navigate the rapidly changing landscape for PN. Additionally, patient videos are utilized throughout to convey key information regarding the burden of PN and optimal management strategies. Upon completion of this activity, participants should be better able to: Discuss the impact on quality of life and economic implications of prurigo nodularis (PN), Describe the pathophysiology of PN as it relates to clinically relevant disease mechanisms and novel therapeutic targets, Evaluate emerging treatment options for PN in the context of mechanism of action, efficacy, and safety, Treat PN in accordance with current evidence and expert recommendations, recognizing that an effective treatment approach should be based on clinical judgment and tailored to the individual needs of the patient.

    Anthony Martinez, MD, AAHIVS, FAASLD - Sharing the Cure: Best Practices for Primary Care Providers to Improve HCV Prevention, Care, and Treatment

    Play Episode Listen Later May 25, 2022 28:42


    Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.

    Joe R. Anderson, PharmD, PhC - Taking the Pulse of Undiagnosed Atrial Fibrillation: Pharmacists as a Lynchpin of Detection and Team-Based Care

    Play Episode Listen Later May 23, 2022 61:42


    Go online to PeerView.com/KMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Screening and diagnosing atrial fibrillation (AF) is vital to implementing guideline-recommended treatment to reduce the risk of stroke. In this activity, an expert panel of pharmacists and a cardiologist discuss risk factors for AF, evidence-based strategies for screening and managing asymptomatic and symptomatic AF, and how multidisciplinary and interdisciplinary approaches to care increase screening and improve patient outcomes. Upon completion of this activity, participants should be better able to: Identify ways that pharmacists can work collaboratively with other clinical colleagues to bridge the gap between patients and healthcare team professionals to improve AF screening, diagnosis, and treatment, Screen individuals who are at risk for stroke due to undiagnosed AF and refer them for further evaluation and treatment, as appropriate, Collaborate with clinical colleagues to ensure that evidence-based, guideline-recommended treatment is discussed and offered to patients with AF to reduce the risk of stroke, Educate patients with AF about the heightened risk of stroke and the importance of anticoagulation therapy.

    Joseph Diaz, MD- Advances in Chronic Spontaneous Urticaria: Expert Insight on Translating Progress to Practice for Improved Symptom Control and Quality of Life

    Play Episode Listen Later May 23, 2022 52:46


    Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient's clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.

    Professor Andrew Menzies-Gow - Tackling the Challenge of Treating Severe Asthma: Taking Aim at the Airway Epithelium

    Play Episode Listen Later May 23, 2022 26:13


    Go online to PeerView.com/MRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in asthma discusses the role of the airway epithelium in severe asthma treatment. Upon completion of this activity, participants should be better able to: Apply the latest pathophysiologic insights into the role of epithelial alarmins in the development of inflammation and structural changes in the airways to the treatment of patients with severe asthma, Discuss the clinical implications of biologic treatment that is not limited by phenotype or biomarker for patients with severe asthma whose disease remains uncontrolled despite standard treatment, Identify patients with severe asthma who may be eligible for treatment with novel biologic therapies that target epithelial alarmins.

    Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

    Play Episode Listen Later May 19, 2022 57:49


    Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

    Bhavana Pothuri, MD, MS - Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer

    Play Episode Listen Later May 16, 2022 28:45


    Go online to PeerView.com/KWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the role of immune checkpoint inhibitors in the care of patients with recurrent and advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Implement appropriate strategies for biomarker testing and integration of novel immunotherapy options into personalized management plans for patients with recurrent or advanced endometrial cancer, in alignment with the latest clinical evidence, approved indications, and guideline recommendations, Employ proactive, collaborative strategies to mitigate and manage immune-related adverse events in patients receiving immune-based therapies for recurrent and advanced endometrial cancers, Apply multidisciplinary, interprofessional, and patient-centric practices and tools that can realistically serve to mitigate disparities in healthcare service delivery and cancer-related outcomes for patients with endometrial cancer.

    Elizabeth Eaman, MD - Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations

    Play Episode Listen Later May 16, 2022 66:58


    Go online to PeerView.com/YDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It is estimated that there are about 1 million adults in the United States who identify as transgender, and this number may be higher depending on the surveys used, the questions asked, and the diversity of subcultures within the transgender community. Although being transgender is not in itself a medical condition, transgender individuals have unique healthcare needs and face barriers to screening and preventive care, particularly with cancer screening. Consequently, these patients may receive lower quality medical care than the general population as a result of stigma, discrimination, and providers' lack of knowledge about gender identity. Additionally, transgender patients may only seek medical care as part of gender affirmation and avoid primary care health concerns, including screenings. This activity, based on a recent live web broadcast, will focus on improving cancer prevention and early detection strategies in the transgender community, as well as enhancing the knowledge and competence of interdisciplinary and interprofessional healthcare providers to appropriately deliver culturally competent care. An interdisciplinary panel of recognized clinical experts will offer learners tactics to improve disease prevention in transgender patients, while the patient advocate will provide the transgender patient perspective throughout the program. Upon completion of this activity, participants should be better able to: Recognize that transgender individuals may be disproportionately at increased risk for contracting HIV and those living with HIV have an increased risk of several types of cancers, Properly screen for and identify cancer in a timely manner to prevent advanced disease in the transgender community, Develop individualized preventive care plans for transgender patients consistent with the patient's current anatomical structure, Provide affirming, inclusive, and culturally humble care to transgender patients to facilitate adherence to clinical recommendations and engagement in care.

    Anjay Rastogi, MD - Making the Case for Preventing and Managing Nephropathy in Patients With Fabry Disease

    Play Episode Listen Later May 13, 2022 35:09


    Go online to PeerView.com/GPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nephrology discusses the prevention and management of nephropathy in patients with Fabry disease. Upon completion of this activity, participants should be better able to: Employ evidence-based tools and strategies to identify patients with FD and prevent nephropathy in a timely manner, Assess safety and efficacy of current and emerging treatments for patients with FD, Apply individualized treatment for patients with FD with an emphasis on preventing nephropathy.

    Michael E. Wechsler, MD - How I Think, How I Treat—Assessing, Managing, and Engaging Patients With Uncontrolled, Moderate to Severe Asthma: Comparing Approaches With Experts Around the World

    Play Episode Listen Later May 13, 2022 63:06


    Go online to PeerView.com/VMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma discuss assessing and managing uncontrolled, moderate to severe asthma for pediatric and adult patients, as well as selecting targeted therapies and improving treatment adherence. Upon completion of this activity, participants should be better able to: Assess the severity of asthma in pediatric and adult patients according to evidence-based practice guidelines, Identify patients that would likely benefit from targeted therapy, considering the relationship between type 2 inflammation, moderate to severe asthma, and comorbid conditions such as atopic dermatitis, Select treatment for pediatric and adult patients with uncontrolled, moderate to severe asthma according to current evidence and guidelines, Use techniques to educate and communicate more effectively with patients and caregivers to better engage them in their care, and improve adherence to individualized treatment plans.

    Claim PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

    In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

    Claim Cancel